BackBioline Rx Overview

Bioline Rx Minority Interest

Bioline Rx's minority interest is $4.2M.

Get informed when a big investor buys or sells

+ Follow
Minority Interest
$4.16M

Peer average

Loading

Bioline Rx Minority Interest History

Loading

Bioline Rx vs. peers: Minority Interest Comparison

Loading

Bioline Rx Minority Interest Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Bioline Rx (BLRX) FAQ

Bioline Rx (BLRX) currently reports a minority interest of $4.2M as of March 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore Bioline Rx's minority interest history and peer comparisons.

Bioline Rx's minority interest changed from $0 to $4.2M (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Bioline Rx reported $4.2M in minority interest as of March 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current minority interest of $4.2M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Bioline Rx, and consider following BLRX for alerts when major investors trade the stock.

Bioline Rx is classified in the Healthcare sector. On minority interest, it currently shows $4.2M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BLRX with unrelated industries.